{"id":1068366,"date":"2022-12-24T00:13:04","date_gmt":"2022-12-24T05:13:04","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/immutep-announces-successful-meeting-with-the-fda-on-eftilagimod-alpha-plus-chemotherapy-for-the-treatment-of-metastatic-breast-cancer\/"},"modified":"2024-08-18T11:46:23","modified_gmt":"2024-08-18T15:46:23","slug":"immutep-announces-successful-meeting-with-the-fda-on-eftilagimod-alpha-plus-chemotherapy-for-the-treatment-of-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/immutep-announces-successful-meeting-with-the-fda-on-eftilagimod-alpha-plus-chemotherapy-for-the-treatment-of-metastatic-breast-cancer.php","title":{"rendered":"Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer"},"content":{"rendered":"<p><![CDATA[SYDNEY, AUSTRALIA, Dec.  23, 2022  (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\"Immutep\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 protein, eftilagimod alpha (\u201cefti\u201d), in conjunction with standard-of-care chemotherapy for the treatment of metastatic breast cancer (MBC). The Company and the FDA have agreed to an integrated Phase II\/III trial design that will help inform a Biologics License Application (BLA).]]><\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/23\/2579122\/0\/en\/Immutep-Announces-Successful-Meeting-with-the-FDA-on-Eftilagimod-Alpha-plus-Chemotherapy-for-the-Treatment-of-Metastatic-Breast-Cancer.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer\">Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068366","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068366"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068366"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068366\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}